Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes
Medical Sciences · 22.12.2025 · 14 (1) · 5
DOI: 10.3390/medsci14010005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 22.12.2025. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ad Hoc Committee on Regenerative Medicine, International Society of Hair Restoration Surgery (ISHRS), Chicago, IL 60608, USA. Hauptthemen laut MEDLINE: Platelet-Rich Plasma, Alopecia, Exosomes, Low-Level Light Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Regenerative therapies have emerged in recent years. In particular, their utility in managing androgenetic alopecia—the most prevalent hair loss condition worldwide, affecting up to half of adults—is an active area of research. Navigating this space can be challenging for physicians due to widespread commercialization, lack of high-quality evidence, and an evolving regulatory landscape.
Objective
To critically review recently published evidence (2020–2025) on platelet-rich plasma, photobiomodulation, stem cells, and exosomes for the treatment of androgenetic alopecia.
Methods
A scoping review was conducted using PubMed, Embase (Ovid) and the Cochrane Controlled Register of Trials in February and November of 2025. Combination therapies were excluded. Results and Conclusions: Platelet-rich plasma is the most studied modality, with emerging investigations into newer formulations such as leukocyte-rich and pure platelet-rich plasma. However, recent studies are limited by inconsistent reporting of cellular composition, short follow-up durations, and a lack of comparative data on treatment protocols. The efficacy of photobiomodulation as a monotherapy remains debated, with inconsistent reporting of device parameters. Stem cells and exosomes show promising, though still limited, clinical evidence in inducing hair regrowth. Standardization of these therapies is crucial, with emphasis on transparency, reproducibility, and patient safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ad Hoc Committee on Regenerative Medicine, International Society of Hair Restoration Surgery (ISHRS), Chicago, IL 60608, USA.
- Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.
- Mediprobe Research Inc., London, ON N5X 2P1, Canada.
- Regeneris Medical, Westwood, MA 02090, USA.
- Department of Dermatology, Mount Sinai Medical Center, New York, NY 10029, USA.
- Unger Medical, New York, NY 10021, USA.
ORCID-Profile: Aditya K Gupta, Tong Wang
Zitieren
APA
Gupta, A. K., Wang, T., Welter, R., Unger, R., & Mejia, R. (2025). Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes. Medical Sciences, 14(1), 5. https://doi.org/10.3390/medsci14010005
Vancouver
Gupta AK, Wang T, Welter R, Unger R, Mejia R. Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes. Medical Sciences. 2025;14(1):5. doi:10.3390/medsci14010005
BibTeX
@article{Gupta2025,
author = {Gupta, Aditya K and Wang, Tong and Welter, Ryan and Unger, Robin and Mejia, Ricardo},
title = {Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes},
journal = {Medical Sciences},
year = {2025},
volume = {14},
number = {1},
pages = {5},
doi = {10.3390/medsci14010005}
}
EUVIMED